Rheumatoid Arthritis Therapeutics Market To Reach $36.39 Billion By 2030

Rheumatoid Arthritis Therapeutics Market Growth & Trends

The global rheumatoid arthritis therapeutics market size is expected to reach USD 36.39 billion by 2030, expanding at a CAGR of 5.93% from 2024 to 2030, according to a new study by Grand View Research, Inc. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth. 

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient’s mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly’s Olumiant and AbbVie’s Upadacitinib are expected to cut down chances of disease remittance.

 Request a free sample copy or view report summary: Rheumatoid Arthritis Therapeutics Market Report

Rheumatoid Arthritis Therapeutics Market Report Highlights

• Biopharmaceuticals segment led the market and accounted for 88.73% of the global revenue in 2023. Biopharmaceuticals are large-molecule drugs that are manufactured, extracted, and synthesized from biological sources.

• Prescription led the market with a market share of 89.64% in 2023. As rheumatologist consultations rise, the prescription segment is expected to remain dominant in the market for rheumatoid arthritis medications over the forecast period.

• North America rheumatoid arthritis therapeutics market accounted for 52.31% share in 2023. The regional market continues to grow and evolve, driven by demographic shifts, advancements in medical research, regulatory changes, and an increasing emphasis on personalized healthcare.

• The Asia Pacific rheumatoid arthritis therapeutics market is experiencing significant growth, driven by the increasing prevalence of rheumatoid arthritis, improving healthcare infrastructure, and advancements in treatment options.

Rheumatoid Arthritis Therapeutics Market Segmentation

Grand View Research has segmented global rheumatoid arthritis therapeutics market report based on molecule, sales channel, and region:

Rheumatoid Arthritis Therapeutics Molecule Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceuticals

  • NSAIDs

  • Analgesics

  • DMARDs

  • Glucocorticoids

• Biopharmaceuticals

  • Biologics

    • TNF-α antagonists

    • T-cell inhibitors

    • CD20 antigen

    • JAK inhibitors

    • anti-IL6 biologics

  • Biosimilars

    • CD20 antigen

    • TNF-α antagonists

Rheumatoid Arthritis Therapeutics Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Prescription

• Over-the-Counter (OTC)

Rheumatoid Arthritis Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • Kuwait

  • UAE

List of Key Players of Rheumatoid Arthritis Therapeutics Market

• AbbVie, Inc.

• Boehringer Ingelheim International GmbH

• Novartis AG

• Regeneron Pharmaceuticals Inc.

• Pfizer, Inc.

• Bristol-Myers Squibb Company

• F. Hoffmann-La Roche Ltd.

• UCB S.A.

• Johnson & Johnson Services, Inc.

• Amgen, Inc.

• Lilly (Eli Lilly and Company)